Physician profile
Kapeel Kumar
NPI 1942439161
$1,249.81
in general payments reported to CMS, 2019-2025
15 companies · $242 in 2025
The $242 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $290 · 2022: $16.95 · 2023: $188 · 2024: $514 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $943.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $943.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $276.19 | 2023-2025 | Jardiance |
| Medtronic, INC. | $164.68 | 2021 | |
| Pfizer INC. | $152.01 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Janssen Scientific Affairs, LLC | $101.96 | 2024 | Xarelto |
| Abbvie INC. | $98.46 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $70.28 | 2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.87 | 2023-2024 | Lifevest |
| Novo Nordisk INC | $50.46 | 2024 | Rybelsus, Ozempic |
| Gilead Sciences, INC. | $34.58 | 2024 | |
| Merck Sharp & Dohme LLC | $30.34 | 2025 | Zerbaxa |
| Novartis Pharmaceuticals Corporation | $26.54 | 2025 | |
| Insmed, INC. | $24.61 | 2023 | Arikayce |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.43 | 2024 | Xifaxan |
| Kestra Medical Technology Services, INC. | $20.41 | 2025 | Assure Wcd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kapeel Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.